Literature DB >> 11317083

National surveillance of HIV-1 subtypes for England and Wales: design, methods, and initial findings.

J V Parry1, G Murphy, K L Barlow, K Lewis, P A Rogers, F J Belda, A Nicoll, C McGarrigle, S Cliffe, P P Mortimer, J P Clewley.   

Abstract

The HIV-1 infections detected in an ongoing national unlinked anonymous HIV surveillance program were subtyped and analyzed according to demographic and risk characteristics. Of the 893 anti--HIV-1--positive specimens allocated to an exposure group, 70% could be subtyped. Almost 25% of infections subtyped were non-B, mostly subtypes A, C, and D. Non-B infections were rare in homosexual and bisexual men and in drug injectors. Forty percent of infections in heterosexual men attending genitourinary medicine clinics were non-B subtypes; of these, 25% were subtype A infections and 59% were subtype C infections. For female clinic attendees, 61% were non-B subtype infections, of which 48% were subtype A infections and 42% were subtype C infections. Of the clinic attendees born in the United Kingdom and Europe, 14% of the men and 35% of the women were infected with non-B subtypes. In contrast, 78% of infections in antenatal patients were non-B subtypes, of which 61% were subtype A and 29% were subtype C. Extrapolation to the estimated 29,700 prevalent adult infections in the United Kingdom indicates that approximately 8,100 (27%) such infections are non-B subtypes and that these are found almost entirely in heterosexuals. The findings suggest spread of infection of non-B subtypes to heterosexuals born in the United Kingdom from individuals infected in regions of high prevalence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317083     DOI: 10.1097/00126334-200104010-00017

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

1.  Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma.

Authors:  Carmen de Mendoza; José Alcamí; María Sainz; Dolores Folgueira; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Use of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strains.

Authors:  Diane L Hirigoyen; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

Review 4.  The HIV Epidemic: High-Income Countries.

Authors:  Sten H Vermund; Andrew J Leigh-Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

5.  Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States.

Authors:  Michael T Pyne; John Hackett; Vera Holzmayer; David R Hillyard
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

6.  Classification of HIV-1 sequences using profile Hidden Markov Models.

Authors:  Sanjiv K Dwivedi; Supratim Sengupta
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

7.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom.

Authors:  Gareth J Hughes; Esther Fearnhill; David Dunn; Samantha J Lycett; Andrew Rambaut; Andrew J Leigh Brown
Journal:  PLoS Pathog       Date:  2009-09-25       Impact factor: 6.823

8.  Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters.

Authors:  Manon Ragonnet-Cronin; Samantha J Lycett; Emma B Hodcroft; Stéphane Hué; Esther Fearnhill; Alison E Brown; Valerie Delpech; David Dunn; Andrew J Leigh Brown
Journal:  J Infect Dis       Date:  2015-12-23       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.